A Phase 3, Randomized, Observer-Blind Study to Evlauate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of the Vaccine Candidate BNT162b2 Against COVID-19 in Healthy Participants 12 Through 50 Years of Age